Chronic Myelogenous Leukemia

Methods of T Cell Depletion Trial (MoTD)

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation

Asciminib Roll-over Study

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

Administration of Donor T Cells With the Caspase-9 Suicide Gene